Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Galapagos Discovers Novel Candidate Drug to Treat Breast Cancer

Published: Monday, April 22, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
GLPG1790 has high efficacy against triple-negative breast cancer.

Galapagos NV has announced that it has developed GLPG1790, a novel candidate drug to treat breast cancer.

GLPG1790 has shown high activity against breast tumors that are triple-negative, for which the absence of estrogen (ER), progesterone (PR) or HER2 receptors affects the prognosis for recovery, and no targeted therapeutic options are currently available.

Breast cancer is a disease in which tumor cells form in the breast tissue; it is one of the most common types of cancer in women. There are many different types of breast cancer, and as a result, there are many options for treatment.

Targeted drug treatments such as Herceptin® and Avastin® attack specific types of breast cancer cells.

Decisions about the best possible treatment with targeted drugs are based on tests for the presence of ER, PR and HER2. Triple-negative breast cancer (tumor cells that have no ER, PR and HER2) accounts for one-fifth of breast cancers, and it usually affects young women. There are no targeted drugs available for patients with triple-negative breast cancer.

Candidate drug GLPG1790 is a selective and potent inhibitor of a novel breast cancer target; the candidate drug has proven to be highly active against triple-negative breast cancer in a mouse xenograft model where it completely blocks tumor growth.

GLPG1790 has good drug-like properties, and safety/tolerability studies with the candidate drug look favorable.

Galapagos will initiate preclinical studies with GLPG1790, and expects to initiate the first clinical trials in humans within one year. This novel program is fully proprietary to Galapagos.

"GLPG1790 is the result of a multi-year research program on a novel mechanism of action discovered with our target discovery platform," says Dr Piet Wigerinck, Galapagos CSO.

Dr Wigerinck continued, "We are pleased to have developed a targeted approach towards triple-negative breast cancer. Targeted approaches in oncology typically show good efficacy and less toxicity than chemotherapy."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ono and Galapagos Sign an Additional Target Discovery Agreement
Collaboration agreement on discovering novel targets in the field of allergic diseases.
Wednesday, May 30, 2012
Galapagos Starts Phase Ib Clinical Study in Cancer Patients
Galapagos plans to assess the safety and explore the preliminary efficacy of GLPG0187 in cancer patients.
Tuesday, March 15, 2011
Galapagos and Roche Expand COPD Alliance
Partners increase the number of antibody targets in the alliance.
Tuesday, May 11, 2010
Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
New Mechanism to Control Human Viral Infections Discovered
Researchers discover long sought after mechanism in human cells that could help treat diseases caused by viruses.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
RNAi Activated in Response to Influenza
Discovery could lead to better ways of combating serious infections, including Ebola and Zika.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Turning Off Asthma Attacks
Researchers discover a critical cellular “off” switch for the inflammatory immune response that causes asthma attacks.
New Strategy May Drop Cancer’s Guard
Scientists eye ways to deconstruct tumors’ protective wall with current diabetes drug.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!